Colorectal carcinoid tumor (neuroendocrine tumor, NET) is a neuroendocrine neoplasm originating from enterochromaffin cells of the colon and rectal mucosa. Rectum is the most commonly involved site (50-60%), followed by cecum and appendix. Rectal carcinoids are usually small (<10 mm), asymptomatic, and incidentally detected. Colorectal NETs account for 20% of GI neuroendocrine tumors. Size is the strongest determinant of metastatic potential: <10 mm carries 2-3% metastasis risk, 10-20 mm 10-15%, and >20 mm 60-80%.
Age Range
35-70
Peak Age
55
Gender
Equal
Prevalence
Uncommon
Carcinoid tumors originate from enterochromaffin (Kulchitsky) cells — these cells are part of the diffuse neuroendocrine system and produce neuroendocrine markers such as serotonin, chromogranin A, and synaptophysin. Serotonin production is usually low in rectal carcinoids (carcinoid syndrome is rare). The tumor begins as a well-defined submucosal nodule and grows slowly. Small tumors (<10 mm) do not breach the muscularis mucosae, medium-sized (10-20 mm) may invade muscularis propria, and large tumors (>20 mm) show transmural invasion and metastasis. On CT, the mucosa is usually intact due to submucosal location — this is an important distinguishing feature. Rectal carcinoids appear as yellow-colored submucosal nodules on endoscopy. Colorectal NETs are classified as well-differentiated (G1-G2, Ki-67 <20%) and poorly differentiated (G3, Ki-67 >20%) — prognosis and treatment approach differ.
Intensely homogeneously enhancing well-defined submucosal nodule in arterial phase with intact mucosal surface — signature finding of colorectal carcinoid. Hypervascularity reflects neuroendocrine origin, submucosal location reflects natural location of enterochromaffin cells.
Well-defined submucosal mass showing intense homogeneous enhancement in arterial phase. Hypervascularity is a characteristic feature of neuroendocrine tumors.
Report Sentence
A submucosal mass measuring approximately ___ mm showing intense enhancement in arterial phase is seen in the rectum; neuroendocrine tumor (carcinoid) should be the primary consideration.
Well-defined intramural/submucosal nodule in portal venous phase. Enhancement persists but may be less than arterial phase. Mucosal surface is smooth and intact.
Report Sentence
The lesion maintains enhancement in portal venous phase with well-defined intramural morphology consistent with submucosal-origin neoplasm.
Well-defined submucosal nodule with intermediate signal on T2W. T2W in the rectum is superior to CT for evaluating muscularis propria invasion.
Report Sentence
The rectal submucosal nodule shows intermediate signal on T2W and its relationship to the muscularis propria should be evaluated.
Marked uptake on Ga-68 DOTATATE PET-CT — somatostatin receptor (SSTR2) positive. Sensitivity 90-95% in well-differentiated NETs (G1-G2). Superior to FDG-PET (FDG may be false negative due to low metabolic activity).
Report Sentence
Marked somatostatin receptor uptake is seen in the rectal lesion on Ga-68 DOTATATE PET-CT, consistent with well-differentiated neuroendocrine tumor.
Hypoechoic, homogeneous, well-defined submucosal nodule on endorectal US. Relationship with muscularis propria layer (invasion present/absent) is clearly evaluated. Gold standard for local staging of rectal carcinoids.
Report Sentence
A hypoechoic, well-defined nodule measuring approximately ___ mm in the submucosa is seen on endorectal US with intact muscularis propria.
Mild to moderate diffusion restriction on DWI. ADC value is generally higher than adenocarcinoma (less aggressive cell density). Provides complementary information for local staging on rectal MRI.
Report Sentence
Mild to moderate diffusion restriction is seen on DWI with ADC value higher than expected for adenocarcinoma.
Criteria
Ki-67 <3%, mitosis <2/10 HPF. Most common type. Slow growth, low metastasis risk.
Distinct Features
Small, homogeneous, intensely enhancing nodule on CT. High uptake on DOTATATE PET. Endoscopic resection is sufficient if <10 mm and muscularis mucosae confined.
Criteria
Ki-67 3-20%, mitosis 2-20/10 HPF. Moderate aggressiveness. Metastasis risk depends on size and invasion depth.
Distinct Features
May be larger on CT, may show mild heterogeneity. Surgical resection usually required. Somatostatin analog therapy (octreotide LAR) applied for metastatic disease.
Criteria
Ki-67 >20%, mitosis >20/10 HPF. Neuroendocrine carcinoma (NEC). Aggressive course, early metastasis.
Distinct Features
Heterogeneous, necrotic mass on CT — may be difficult to differentiate from adenocarcinoma. FDG-PET positive, DOTATATE PET may be negative. Small cell carcinoma-like treatment (cisplatin + etoposide).
Distinguishing Feature
Adenocarcinoma appears as mucosal-origin, lumen-narrowing, heterogeneously enhancing mass. Carcinoid is submucosal-origin, well-defined, homogeneously hypervascular nodule with usually intact mucosa.
Distinguishing Feature
GIST is usually larger, exophytic, and shows irregular enhancement. Rare in colorectum. Carcinoid is smaller, intramural/submucosal, and homogeneously hypervascular.
Distinguishing Feature
Leiomyoma originates from muscularis propria, shows low-moderate enhancement. Carcinoid originates from submucosa and shows intense arterial phase enhancement (hypervascular).
Distinguishing Feature
Lymphoma shows longer segment involvement, homogeneous low-moderate enhancement, and aneurysmal dilation. Carcinoid is a focal, well-defined submucosal nodule that is hypervascular.
Urgency
routineManagement
surgicalBiopsy
NeededFollow-up
6-monthTreatment of rectal carcinoids depends on size and invasion depth: <10 mm and muscularis mucosae confined → endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD); 10-20 mm → decision after MR/EUS evaluation of muscularis propria invasion (no invasion: ESD, invasion: surgery); >20 mm or muscularis propria invaded → surgical resection + lymph node dissection. Ga-68 DOTATATE PET-CT is mandatory for staging and treatment planning in metastatic disease. If somatostatin receptor positive, octreotide LAR and/or PRRT (Lu-177 DOTATATE) are treatment options. Follow-up: chromogranin A + CT/MR every 6 months (first 3 years), then annually.
Most rectal NETs are <1 cm with good prognosis. Metastasis risk increases in >2 cm tumors. Endoscopic resection is curative for small tumors. Carcinoid syndrome is rare in colorectal NETs.